Why did BIO-key (BKYI) stock go up? A new Middle East agency customer

What happened

BIO-key International closed Tuesday at $2.83, up about 72% from Monday’s $1.65. It opened at about $4.11 and closed about 31% below that level. About 82 million shares traded, against an average of about 5.8 million over the prior 30 sessions. That average is itself inflated by one day, 29 September, when about 170 million shares traded.

BIO-key provides identity and access management software, including its PortalGuard platform and fingerprint biometrics.

The likely catalyst

Before the open, BIO-key said that “another Middle East government security agency, a new customer for the Company” had selected its Multi-Factor Authentication (MFA) and Single Sign-On (SSO) platform. The deployment protects access to the agency’s core communications infrastructure, including web-based services, and is “nearing completion”. BIO-key said the deal went from first talks to agreement in under two months. IT Harmony, its value-added distribution partner in the Gulf, supported the work.

What the release doesn’t say:

• the agency’s name or country (the dateline is Riyadh and Holmdel, N.J.);
• the contract value, length, user count or when revenue is recognised.

We found no 8-K for the announcement as of 14 October.

A second release the same morning named Stephen Morrow President of PortalGuard, succeeding Mark Cochran, who retired.

This is the second spike on a Gulf announcement in two weeks. On 29 September BIO-key announced a partnership with Dubai-based Al Majlis Group, also with no value disclosed. The stock closed up about 86% that day at $3.12, then slid back to $1.65 by 12 October.

The share count is small. BIO-key had 2,035,149 shares at 30 September, after a 1-for-10 reverse split on 30 April. At Tuesday’s close the company was valued at about $5.8 million, and the day’s volume was about 40 times the share count.

Money and dilution check

At 30 June, BIO-key had $1.38 million of cash and used $1.20 million in operations in the first half. It says it needs about $750,000 a month to run the business, doesn’t have enough cash for twelve months, and carries going-concern language. In August it raised about $2.5 million gross when Armistice Capital exercised warrants at a reduced price of $4.06. 10-Q.

The share count has nearly doubled since the split, from about 1.09 million in April. Part of that came from paying off a Streeterville Capital note with stock: three exchanges from July to 29 September, the last for 247,805 shares, left the note paid in full.

The main overhang is the August deal’s new warrants: 1,236,668 shares at $4.06, about 61% of the current count. They can’t be exercised until stockholders approve them under Nasdaq Rule 5635(d). That proposal has failed to pass twice, and the meeting resumes on 30 October. A resale S-1 filed 9 October covers those shares. Full cash exercise would bring in about $5.0 million and lift the count to about 3.27 million. Tuesday’s close was below the $4.06 strike. See S-1 vs S-3.

On listing: Nasdaq suspended the stock on 13 May over the $1.00 bid rule and a late 10-K. Trading resumed on 8 July after a hearing, and BIO-key is under a Panel Monitor until 6 July 2027. 8-K. See the Nasdaq delisting process.

How we measured: regular-session close to close, from Alpaca Markets (SIP) daily bars, split-adjusted. Volume is compared with the average of the 30 trading sessions before the move.